RET and thyroid cancer: Somatic mutations in RAS, PIK3CA, KMT2C, and/or BRAFV600E, as well as somatic RET/PTC rearrangements could act as a somatic “second-hit” in the development of other forms of thyroid cancers in affected individuals [9, 134, 138].